12 studies found for:    1. RIVER PCI
Show Display Options
Rank Status Study
1 Active, not recruiting Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Conditions: Coronary Artery Disease;   Angina Pectoris
Interventions: Drug: Ranolazine;   Drug: Placebo
2 Terminated Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Coronary Artery Disease;   Percutaneous Coronary Intervention
Interventions: Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;   Drug: Plavix (clopidogrel 75 mg) and aspirin
3 Completed Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673);   Drug: Otamixaban matching placebo;   Drug: Unfractionated Heparin;   Drug: Unfractionated Heparin matching placebo;   Drug: Eptifibatide;   Drug: Eptifibatide matching placebo
4 Completed Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Radiation: Prophylactic Cranial Irradiation (PCI)
5 Completed The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
Condition: Angioplasty, Transluminal, Percutaneous Coronary
Interventions: Drug: Otamixaban (XRP0673);   Drug: Unfractionated Heparin;   Procedure: Percutaneous Coronary Intervention
6 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
7 Active, not recruiting Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Fallopian Tube Cancer;   Neurotoxicity;   Ovarian Cancer;   Pain;   Peripheral Neuropathy;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: glutathione;   Drug: paclitaxel;   Other: placebo
8 Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
9 Active, not recruiting The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Darapladib 160 mg;   Drug: Placebo
10 Completed
Has Results
S0222: Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: cisplatin;   Drug: etoposide;   Drug: tirapazamine;   Radiation: radiation therapy
11 Recruiting PRE-DETERMINE Cohort Study
Conditions: Coronary Artery Disease;   Left Ventricular Dysfunction;   Sudden Cardiac Death
Intervention:
12 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:

Indicates status has not been verified in more than two years